GEAP202416398A - Methods of treating mitochondria-related disorders - Google Patents
Methods of treating mitochondria-related disordersInfo
- Publication number
- GEAP202416398A GEAP202416398A GEAP202416398A GEAP2024016398A GEAP202416398A GE AP202416398 A GEAP202416398 A GE AP202416398A GE AP202416398 A GEAP202416398 A GE AP202416398A GE AP2024016398 A GEAP2024016398 A GE AP2024016398A GE AP202416398 A GEAP202416398 A GE AP202416398A
- Authority
- GE
- Georgia
- Prior art keywords
- methods
- methyl
- related disorders
- dinitrophenoxy
- imidazole
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163191321P | 2021-05-20 | 2021-05-20 | |
| US202163222841P | 2021-07-16 | 2021-07-16 | |
| US202263307515P | 2022-02-07 | 2022-02-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEAP202416398A true GEAP202416398A (en) | 2024-01-25 |
Family
ID=82020295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP202416398A GEAP202416398A (en) | 2021-05-20 | 2022-05-19 | Methods of treating mitochondria-related disorders |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250177353A1 (https=) |
| EP (1) | EP4340829A1 (https=) |
| JP (1) | JP2024521709A (https=) |
| KR (1) | KR20240021827A (https=) |
| AU (1) | AU2022275935A1 (https=) |
| BR (1) | BR112023024146A2 (https=) |
| CA (1) | CA3219548A1 (https=) |
| CL (1) | CL2023003441A1 (https=) |
| GE (1) | GEAP202416398A (https=) |
| IL (1) | IL308669A (https=) |
| JO (1) | JOP20230298A1 (https=) |
| MX (1) | MX2023013688A (https=) |
| TW (1) | TW202313010A (https=) |
| WO (1) | WO2022246039A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023150759A1 (en) * | 2022-02-07 | 2023-08-10 | Rivus Pharmaceuticals, Inc. | Methods of weight loss in a subject with elevated hba1c |
| TW202515545A (zh) * | 2023-08-10 | 2025-04-16 | 大陸商深圳君聖泰生物技術有限公司 | ２，４－二硝苯酚之衍生物以及前藥、以及其組成物以及方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1098641B1 (en) | 1998-07-27 | 2016-04-27 | St. Jude Pharmaceuticals, Inc. | Chemically induced intracellular hyperthermia |
| PT3565806T (pt) | 2017-01-06 | 2022-05-19 | Rivus Pharmaceuticals Inc | Novos derivados de fenilo |
-
2022
- 2022-05-19 WO PCT/US2022/029992 patent/WO2022246039A1/en not_active Ceased
- 2022-05-19 KR KR1020237043901A patent/KR20240021827A/ko active Pending
- 2022-05-19 BR BR112023024146A patent/BR112023024146A2/pt unknown
- 2022-05-19 AU AU2022275935A patent/AU2022275935A1/en active Pending
- 2022-05-19 IL IL308669A patent/IL308669A/en unknown
- 2022-05-19 JP JP2023571818A patent/JP2024521709A/ja active Pending
- 2022-05-19 GE GEAP202416398A patent/GEAP202416398A/en unknown
- 2022-05-19 MX MX2023013688A patent/MX2023013688A/es unknown
- 2022-05-19 US US18/562,560 patent/US20250177353A1/en active Pending
- 2022-05-19 EP EP22729956.7A patent/EP4340829A1/en active Pending
- 2022-05-19 CA CA3219548A patent/CA3219548A1/en active Pending
- 2022-05-20 TW TW111118998A patent/TW202313010A/zh unknown
-
2023
- 2023-11-19 JO JOJO/P/2023/0298A patent/JOP20230298A1/ar unknown
- 2023-11-20 CL CL2023003441A patent/CL2023003441A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4340829A1 (en) | 2024-03-27 |
| KR20240021827A (ko) | 2024-02-19 |
| JP2024521709A (ja) | 2024-06-04 |
| CL2023003441A1 (es) | 2024-05-10 |
| JOP20230298A1 (ar) | 2023-11-19 |
| US20250177353A1 (en) | 2025-06-05 |
| TW202313010A (zh) | 2023-04-01 |
| WO2022246039A1 (en) | 2022-11-24 |
| AU2022275935A1 (en) | 2023-12-07 |
| BR112023024146A2 (pt) | 2024-01-30 |
| CA3219548A1 (en) | 2022-11-24 |
| MX2023013688A (es) | 2024-02-27 |
| IL308669A (en) | 2024-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEAP202416398A (en) | Methods of treating mitochondria-related disorders | |
| Kohler et al. | Mechanisms of vascular damage in obstructive sleep apnea | |
| Tamisier et al. | Sleep biology updates: hemodynamic and autonomic control in sleep disorders | |
| EA200500583A1 (ru) | Ингибиторы белка-регулятора трансмембранной проводимости при муковисцидозе и их применение | |
| EA202193190A1 (ru) | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов | |
| AR114392A1 (es) | Tratamiento de pacientes con enfermedad de fabry clásica | |
| RU2011108486A (ru) | ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ ПЕПТИДА Wnt5-a ДЛЯ ЛЕЧЕНИЯ МЕЛАНОМЫ И РАКА ЖЕЛУДКА | |
| DK1677806T3 (da) | Sammensætninger til behandling af akut og overbelastningsforårsaget forstuvning og forstrækning ved anvendelse af hyaluronsyre | |
| CY1111783T1 (el) | Θεραπεια συνδυασμου διαταραχων κατωτερης ουροποιητικης οδου με 2 προσδεματα και μη στεροειδες αντιφλεγμονωδες φαρμακο | |
| Deek | BPC 157 as potential treatment for COVID-19 | |
| Lassen et al. | Conservative treatment of gangrene using mineralocorticoid-induced moderate hypertension | |
| JPH02180828A (ja) | 男性不能症の治療用物質 | |
| BR112022019858A2 (pt) | Métodos de tratamento de esclerose sistêmica | |
| WO2021202546A8 (en) | Early drug interventions to reduce covid-19 related respiratory distress, need for ventilator assistance and death | |
| Hao et al. | Feasibility of 5-aminolevulinic acid mediated photodynamic therapy for male genital lichen sclerosus | |
| CN1261136C (zh) | 治疗腰腿痛的外用贴膏 | |
| RU2147851C1 (ru) | Способ лечения остеоартроза, осложненного синовитом и функциональными контрактурами суставов | |
| Seifi et al. | Effect of intravenous regional anesthesia with spinal block on foot surgeries: A double-blinded randomized clinical trial | |
| RU2818151C1 (ru) | Способ восстановления пассивного сгибания в локтевом суставе у детей с артрогрипозом | |
| RU2295349C2 (ru) | Способ лечения остеоартроза коленных суставов с использованием внутрисуставного введения препарата "хондролон" | |
| TW202611065A (zh) | pUDK-HGF注射液的用途 | |
| CN112823802A (zh) | 一种治疗风湿性关节炎的外用中药液 | |
| Negm et al. | Laser-assisted uvulopalatoplasty: post operative complications (NILES, preliminary experience) | |
| JPWO2022158992A5 (https=) | ||
| CN107233417A (zh) | 一种治疗糖尿病的外用中药 |